What is new about TRIUMPH-1 compared with the earlier Retatrutide data?

TRIUMPH-1 is the first pivotal Phase 3 trial in a broad obesity population without type 2 diabetes. TRIUMPH-4 (December 2025) concerned obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) concerned type 2 diabetes. TRIUMPH-1 comes closest to the core indication.

How much weight loss was reported?

After 80 weeks, mean weight loss was 19.0 % (4 mg), 25.9 % (9 mg) and 28.3 % (12 mg) versus -2.2 % on placebo. In the 12 mg group, 45.3 % reached a loss of at least 30 %.

Why does a triple agonist work more strongly?

Retatrutide activates GLP-1, GIP and glucagon simultaneously. GLP-1 and GIP mainly influence appetite and insulin signaling, while the additional glucagon agonism increases energy expenditure. This combination is regarded as the mechanistic explanation for the high values.

Is Retatrutide approved?

No. Retatrutide is in clinical development and is not approved as a medicine. It is a research peptide. This article reports exclusively on trial data.

When will full data be available?

Eli Lilly will present the detailed data at the ADA Scientific Sessions on 6 June 2026. Only then will subgroups and the full safety profile be assessable.

Retatrutide TRIUMPH-1: Up to 28.3 % Weight Loss in the Pivotal Phase 3 Obesity Trial (May 2026)

Important note: This article serves scientific information and research purposes only. Retatrutide is a research peptide, not intended for human consumption and not approved as a medicine anywhere. No therapeutic recommendations or usage instructions are given.

TL;DR: What was reported on 21 May 2026

Date: 21 May 2026, topline press release from Eli Lilly. Key finding: In TRIUMPH-1, the first pivotal Phase 3 obesity trial, Retatrutide achieved a mean weight loss after 80 weeks of 19.0 % (4 mg), 25.9 % (9 mg) and 28.3 % (12 mg) versus -2.2 % on placebo. Trial size: 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, but without type 2 diabetes. Relevance: TRIUMPH-1 is the broad non-diabetic trial on the path to the core obesity submission. Detailed data follow at the ADA Scientific Sessions on 6 June 2026.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

What this is about: TRIUMPH-1 is not TRIUMPH-4

Retatrutide is Eli Lilly's triple agonist, which simultaneously activates the receptors for GLP-1, GIP and glucagon. The peptide has delivered several Phase 3 readouts in 2026, and this is exactly where confusion often arises. TRIUMPH-1 is a separate, new trial and should not be mixed up with the readouts already reported:

TRIUMPH-4 (December 2025): cohort with obesity and knee osteoarthritis.
TRANSCEND-T2D-1 (March 2026): cohort with type 2 diabetes.
TRIUMPH-1 (May 2026): broad population with obesity or overweight plus a comorbidity, explicitly without type 2 diabetes.

TRIUMPH-1 is therefore the trial that comes closest to the core indication: obesity in a typical, non-diabetic population. It is designed as a primary registration trial.

The key numbers from the TRIUMPH-1 topline

The randomized, placebo-controlled trial assigned 2,339 participants across three Retatrutide doses and placebo. The primary timepoint was week 80.

Group	Mean weight loss (week 80)	Share with at least 30 % loss	Discontinuation due to side effects
Retatrutide 4 mg	19.0 %	15.3 %	4.1 %
Retatrutide 9 mg	25.9 %	37.9 %	6.9 %
Retatrutide 12 mg	28.3 %	45.3 %	11.3 %
Placebo	-2.2 %	0.5 %	4.9 %

The dose-response curve is clear: as the dose rises, weight loss increases, and in the 12 mg group nearly one in two people reached a loss of at least 30 % of body weight. According to Eli Lilly, all primary and key secondary endpoints were met.

Trial design in brief

Phase 3, randomized, double-blind, placebo-controlled. 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, without type 2 diabetes. Three dose arms (4, 9, 12 mg, once weekly subcutaneous) against placebo. Primary endpoint: percentage weight loss after 80 weeks. The values reported here come from the topline press release; the full data presentation takes place at the ADA Scientific Sessions on 6 June 2026.

Context: a magnitude close to bariatric surgery

A mean weight loss of 28.3 % in a broad, non-diabetic obesity population is a magnitude that until now was mainly known from bariatric surgery. For comparison, approved GLP-1 agents deliver considerably lower values in comparable trials, and dual agonists sit in between. The additional glucagon arm of the triple agonist is regarded as the mechanistic explanation: while GLP-1 and GIP mainly influence appetite and insulin signaling, glucagon agonism increases energy expenditure.

Important for the scientific context: these numbers are a manufacturer's topline report, not a peer-reviewed publication. The full data, including subgroups and safety details, will only become assessable with the ADA presentation and a later publication.

Safety and tolerability signals

Tolerability: mainly gastrointestinal

As with the entire incretin class, the most common side effects were gastrointestinal (nausea, diarrhea, constipation), predominantly mild to moderate and dose-dependent. The discontinuation rate due to side effects rose with the dose: 4.1 % (4 mg), 6.9 % (9 mg) and 11.3 % (12 mg) versus 4.9 % on placebo. The full safety profile, including rarer signals, will only become assessable with the detailed presentation.

The higher discontinuation rate in the 12 mg arm is the price for the strongest effect and underscores why gradual titration and assessment by professionals are central in clinical development. For research, the dose-response and dose-tolerability relationship is the genuinely interesting part of the readout.

What comes next

Eli Lilly has announced that it will present the data in detail at the ADA Scientific Sessions on 6 June 2026. TRIUMPH-1 is part of the broader TRIUMPH program, whose further readouts are expected throughout 2026 and which together are intended to form the basis for a core obesity submission. A regulatory approval has not been granted at this point.